BACKGROUND: Dysfunctioning of CCAAT/enhancer binding protein α (C/EBPα) in acute myeloid leukemia can be caused, amongst others, by mutations in the encoding gene (CEBPA) and by promoter hypermethylation. CEBPA-mutated acute myeloid leukemia is associated with a favorable outcome, but this may be restricted to the case of double mutations in CEBPA in adult acute myeloid leukemia. In pediatric acute myeloid leukemia, data on the impact of these mutations are limited to one series, and data on promoter hypermethylation are lacking. Our objective was to investigate the characteristics, gene expression profiles and prognostic impact of the different CEBPA aberrations in pediatric acute myeloid leukemia. DESIGN AND METHODS: We screened a large pediatric cohort (n=252) for CEBPA single and double mutations by direct sequencing, and for promoter hypermethylation by methylation-specific polymerase chain reaction. Furthermore, we determined the gene-expression profiles (Affymetrix HGU133 plus 2.0 arrays) of this cohort (n=237). RESULTS: Thirty-four mutations were identified in 20 out of the 252 cases (7.9%), including 14 double-mutant and 6 single-mutant cases. CEBPA double mutations conferred a significantly better 5-year overall survival compared with single mutations (79% versus 25%, respectively; P=0.04), and compared with CEBPA wild-type acute myeloid leukemia excluding core-binding factor cases (47%; P=0.07). Multivariate analysis confirmed that the double mutations were an independent favorable prognostic factor for survival (hazard ratio 0.23, P=0.04). The combination of screening for promoter hypermethylation and gene expression profiling identified five patients with silenced CEBPA, of whom four cases relapsed. All cases characteristically expressed T-lymphoid markers. Moreover, unsupervised clustering of gene expression profiles showed a clustering of CEBPA double-mutant and silenced cases, pointing towards a common hallmark of abrogated C/EBPα-functioning in these acute myeloid leukemias. CONCLUSIONS: We showed the independent favorable outcome of patients with CEBPA double-mutant acute myeloid leukemia in a large pediatric series. This molecular marker may, therefore, improve risk-group stratification in pediatric acute myeloid leukemia. For the first time, CEBPA-silenced cases are suggested to confer a poor outcome in pediatric acute myeloid leukemia, indicating that further investigation of this aberration is needed. Furthermore, clustering of gene expression profiles provided insight into the biological similarities and diversities of the different aberrations in CEBPA in pediatric acute myeloid leukemia.
BACKGROUND: Dysfunctioning of CCAAT/enhancer binding protein α (C/EBPα) in acute myeloid leukemia can be caused, amongst others, by mutations in the encoding gene (CEBPA) and by promoter hypermethylation. CEBPA-mutated acute myeloid leukemia is associated with a favorable outcome, but this may be restricted to the case of double mutations in CEBPA in adult acute myeloid leukemia. In pediatric acute myeloid leukemia, data on the impact of these mutations are limited to one series, and data on promoter hypermethylation are lacking. Our objective was to investigate the characteristics, gene expression profiles and prognostic impact of the different CEBPA aberrations in pediatric acute myeloid leukemia. DESIGN AND METHODS: We screened a large pediatric cohort (n=252) for CEBPA single and double mutations by direct sequencing, and for promoter hypermethylation by methylation-specific polymerase chain reaction. Furthermore, we determined the gene-expression profiles (Affymetrix HGU133 plus 2.0 arrays) of this cohort (n=237). RESULTS: Thirty-four mutations were identified in 20 out of the 252 cases (7.9%), including 14 double-mutant and 6 single-mutant cases. CEBPA double mutations conferred a significantly better 5-year overall survival compared with single mutations (79% versus 25%, respectively; P=0.04), and compared with CEBPA wild-type acute myeloid leukemia excluding core-binding factor cases (47%; P=0.07). Multivariate analysis confirmed that the double mutations were an independent favorable prognostic factor for survival (hazard ratio 0.23, P=0.04). The combination of screening for promoter hypermethylation and gene expression profiling identified five patients with silenced CEBPA, of whom four cases relapsed. All cases characteristically expressed T-lymphoid markers. Moreover, unsupervised clustering of gene expression profiles showed a clustering of CEBPA double-mutant and silenced cases, pointing towards a common hallmark of abrogated C/EBPα-functioning in these acute myeloid leukemias. CONCLUSIONS: We showed the independent favorable outcome of patients with CEBPA double-mutant acute myeloid leukemia in a large pediatric series. This molecular marker may, therefore, improve risk-group stratification in pediatric acute myeloid leukemia. For the first time, CEBPA-silenced cases are suggested to confer a poor outcome in pediatric acute myeloid leukemia, indicating that further investigation of this aberration is needed. Furthermore, clustering of gene expression profiles provided insight into the biological similarities and diversities of the different aberrations in CEBPA in pediatric acute myeloid leukemia.
Authors: Bas J Wouters; Meritxell Alberich Jordà; Karen Keeshan; Irene Louwers; Claudia A J Erpelinck-Verschueren; Dennis Tielemans; Anton W Langerak; Yiping He; Yumi Yashiro-Ohtani; Pu Zhang; Christopher J Hetherington; Roel G W Verhaak; Peter J M Valk; Bob Löwenberg; Daniel G Tenen; Warren S Pear; Ruud Delwel Journal: Blood Date: 2007-08-01 Impact factor: 22.113
Authors: Pieter Van Vlierberghe; Martine van Grotel; H Berna Beverloo; Charles Lee; Tryggvi Helgason; Jessica Buijs-Gladdines; Monique Passier; Elisabeth R van Wering; Anjo J P Veerman; Willem A Kamps; Jules P P Meijerink; Rob Pieters Journal: Blood Date: 2006-07-27 Impact factor: 22.113
Authors: Bas J Wouters; Bob Löwenberg; Claudia A J Erpelinck-Verschueren; Wim L J van Putten; Peter J M Valk; Ruud Delwel Journal: Blood Date: 2009-01-26 Impact factor: 22.113
Authors: Sahar Barjesteh van Waalwijk van Doorn-Khosrovani; Claudia Erpelinck; Joost Meijer; Susanna van Oosterhoud; Wim L J van Putten; Peter J M Valk; H Berna Beverloo; Daniel G Tenen; Bob Löwenberg; Ruud Delwel Journal: Hematol J Date: 2003
Authors: Peggy Kirstetter; Mikkel B Schuster; Oksana Bereshchenko; Susan Moore; Heidi Dvinge; Elke Kurz; Kim Theilgaard-Mönch; Robert Månsson; Thomas A Pedersen; Thomas Pabst; Evelin Schrock; Bo T Porse; Sten Eirik W Jacobsen; Paul Bertone; Daniel G Tenen; Claus Nerlov Journal: Cancer Cell Date: 2008-04 Impact factor: 31.743
Authors: Jasmijn D E de Rooij; Marry M van den Heuvel-Eibrink; Malou C H Hermkens; Lonneke J Verboon; Susan T C J M Arentsen-Peters; Maarten Fornerod; Andre Baruchel; Jan Stary; Dirk Reinhardt; Valerie de Haas; Rob Pieters; C Michel Zwaan Journal: Haematologica Date: 2015-01-16 Impact factor: 9.941
Authors: C Michel Zwaan; Edward A Kolb; Dirk Reinhardt; Jonas Abrahamsson; Souichi Adachi; Richard Aplenc; Eveline S J M De Bont; Barbara De Moerloose; Michael Dworzak; Brenda E S Gibson; Henrik Hasle; Guy Leverger; Franco Locatelli; Christine Ragu; Raul C Ribeiro; Carmelo Rizzari; Jeffrey E Rubnitz; Owen P Smith; Lillian Sung; Daisuke Tomizawa; Marry M van den Heuvel-Eibrink; Ursula Creutzig; Gertjan J L Kaspers Journal: J Clin Oncol Date: 2015-08-24 Impact factor: 44.544
Authors: Marjolein Blink; Martin Zimmermann; Christine von Neuhoff; Dirk Reinhardt; Valerie de Haas; Henrik Hasle; Maureen M O'Brien; Batia Stark; Julie Tandonnet; Andrea Pession; Katerina Tousovska; Daniel K L Cheuk; Kazuko Kudo; Takashi Taga; Jeffrey E Rubnitz; Iren Haltrich; Walentyna Balwierz; Rob Pieters; Erik Forestier; Bertil Johansson; Marry M van den Heuvel-Eibrink; C Michel Zwaan Journal: Haematologica Date: 2013-08-09 Impact factor: 9.941
Authors: V Grossmann; U Bacher; A Kohlmann; K Butschalowski; A Roller; S Jeromin; F Dicker; W Kern; S Schnittger; T Haferlach; C Haferlach Journal: Blood Cancer J Date: 2012-08-31 Impact factor: 11.037